Lexeo Therapeutics stock soars after FDA accelerated approval progress
Lexeo Therapeutics stock soars after FDA accelerated approval progress
Source link
Similar Posts
Stock Radar| Mphasis stock sees profit taking from 52-week highs; should you buy the dip?
“Mphasis stock has been maintaining its bullish momentum and seen rising in formation of higher bottom pattern. Traders can buy for a target of Rs 3350-3400 in the next 1-2 months,” Shitij Gandhi, Senior Technical Analyst, SMC Global Securities, said. Show more Show less Source link
ASX200 Current Performance
Just not getting the last 3 days trade from the index point of view. The US (S&P500) europe (dax) all are strong and have been over the past week. Also no great moves on commodity markets, if anything copper, metal commodities are supportive. Why has our index creeping sideway for 3 days??? Source link
China’s aging population fuels ‘silver economy’ boom, but profits can prove elusive
HONG KONG (AP) — Every Wednesday, retiree Zhang Zhili travels an hour by bus to an education center, drawn by the pulsing rhythms of the African drum she plays there in a classroom filled with fellow retirees whose hands move in unison, every beat lifting her spirits. Zhang, 71, has found joy and new friends…
Coal India board approves up to 35% divestment in SECL via OFS and up to 25% in Mahanadi Coalfields
Coal India Limited’s board on Monday gave an in-principle approval to divest up to 35% stake in its subsidiary South Eastern Coalfields Limited (SECL). The board also approved up to a 25% stake sale in another wholly-owned subsidiary Mahanadi Coalfields Limited (MCL). In a meeting held today, the board approved the divestment of up to…
